VYNE Therapeutics Inc. announced that members of management will attend the Biotechnology Innovation Organization International Convention, taking place June 5-8, 2023 at the Boston Convention & Exhibition Center in Boston, Massachusetts.
BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that members of management will attend the Biotechnology Innovation Organization (BIO) International Convention, taking place June 5-8, 2023 at the Boston Convention & Exhibition Center in Boston, Massachusetts.
The Company will be attending the conference and participating in partnering meetings and 1-on-1 meetings with investors. VYNE management will be available to review its pipeline of unique and proprietary bromodomain & extra-terminal (BET) domain inhibitors.
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain inhibitors, which comprise its InhiBET™ platform, includes a locally administered pan-BET inhibitor (VYN201) and an orally available BD2-selective BET inhibitor (VYN202) that were licensed from Tay Therapeutics Limited.
For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com
